Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 478,300 shares, an increase of 5.6% from the August 31st total of 452,800 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is presently 7.8 days. Approximately 3.5% of the shares of the stock are short sold.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Monday, August 12th.
Read Our Latest Analysis on ACXP
Institutional Investors Weigh In On Acurx Pharmaceuticals
Acurx Pharmaceuticals Stock Up 1.1 %
Acurx Pharmaceuticals stock opened at $1.92 on Wednesday. The company’s 50-day moving average price is $2.06 and its 200-day moving average price is $2.16. The company has a market cap of $30.42 million, a PE ratio of -1.63 and a beta of -1.72. Acurx Pharmaceuticals has a twelve month low of $1.17 and a twelve month high of $8.82.
Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the business earned ($0.28) EPS. As a group, sell-side analysts expect that Acurx Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- How to Use Stock Screeners to Find Stocks
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Health Care Stocks Explained: Why You Might Want to Invest
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.